Peptide hormones

MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29

Retrieved on: 
Friday, June 25, 2021

WESTLAKE VILLAGE, Calif., June 25, 2021 /PRNewswire/ --MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present two posters at the American Diabetes Association's virtual 81st Scientific Sessions, June 25-29.

Key Points: 
  • WESTLAKE VILLAGE, Calif., June 25, 2021 /PRNewswire/ --MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present two posters at the American Diabetes Association's virtual 81st Scientific Sessions, June 25-29.
  • MannKind is also hosting a booth in the virtual Exhibit Hall at the Scientific Sessions.
  • An insulin regimen that closely mimics physiologic insulin for pediatric patients with type 1 diabetes (T1D) remains a critical goal.
  • Afrezza an ultra rapid-acting dry-powder prandial insulin is currently indicated to improve glycemic control in adults with T1D or type 2 (T2D) diabetes.

Carmot Therapeutics Initiates the Clinical Program for CT-388, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Patients with Type 2 Diabetes and Showcases its Technology at the Upcoming American Diabetes Association Scientific Session

Retrieved on: 
Thursday, June 24, 2021

Carmots growing portfolio of novel therapeutics for the treatment of type 2 diabetes, obesity and other metabolic diseases will also be showcased through a video at the American Diabetes Association 81st Scientific Sessions.

Key Points: 
  • Carmots growing portfolio of novel therapeutics for the treatment of type 2 diabetes, obesity and other metabolic diseases will also be showcased through a video at the American Diabetes Association 81st Scientific Sessions.
  • CT-388 is a fully biased dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor, anticipated to be dosed once-weekly.
  • About Carmot Therapeutics, Inc. Carmot Therapeutics (Carmot) is focused on the discovery and development of disease-modifying therapies for patients living with metabolic diseases and cancer.
  • Carmot applies Chemotype Evolution (CE), a pioneering drug discovery technology, in combination with unique biological expertise to identify innovative and superior therapeutics.

2021 Insights on Islet Amyloid Polypeptide Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021

The "Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 17 molecules.
  • The latest report Islet Amyloid Polypeptide - Drugs in Development, 2021, outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone.

Amalgam Rx™ Receives CE Mark for Basal Insulin Titration

Retrieved on: 
Wednesday, June 16, 2021

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformit Europenne (CE) Mark for its insulin titration application, iSage Rx and its white-labeled variants.

Key Points: 
  • Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformit Europenne (CE) Mark for its insulin titration application, iSage Rx and its white-labeled variants.
  • View the full release here: https://www.businesswire.com/news/home/20210616005524/en/
    Amalgam Rx Receives CE Mark for Basal Insulin Titration (Graphic: Business Wire)
    With this CE Mark, iSage Rxs capacity to support the titration of all basal insulins and enable connectivity to the leading Bluetooth-enabled blood glucose meters from Roche, Lifescan, and Ascensia, is now cleared for the European market.
  • In early clinical studies, the iSage Rx app has demonstrated the ability to improve patients glucose levels by helping them reach the appropriate level of basal insulin.
  • Amalgam is the manufacturer of the iSage Rx app and white-labeled variants, the first prescription-only mobile application for the automated titration of all brands of basal insulin to receive market authorization in the United States, EU, and Brazil.

Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions

Retrieved on: 
Wednesday, June 16, 2021

Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions

Key Points: 
  • Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions
    Company to present six abstracts on ZEGALOGUE(dasiglucagon) injection, including one oral presentation
    Copenhagen, DK and Boston, MA, U.S. June 16, 2021 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • "We are proud to share such a robust set of clinical data at this years ADA medical meeting, said Adam Steensberg, Executive Vice President, Research & Development of Zealand Pharma.
  • ZEGALOGUE is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines.

Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

Retrieved on: 
Friday, June 11, 2021

Poster presentation demonstrates that KER-050 had effects on multiple stages of erythroblast maturation (both early- and late-stage) and increased circulating erythropoietin in preclinical models.

Key Points: 
  • Poster presentation demonstrates that KER-050 had effects on multiple stages of erythroblast maturation (both early- and late-stage) and increased circulating erythropoietin in preclinical models.
  • We are pleased to be able to present multiple posters at this years EHA2021 Virtual Congress.
  • Our preclinical studies continue to elucidate the relationship between ALK2 inhibition, hepcidin and serum iron.
  • In addition, the data suggests that ALK2 inhibition has the potential to mobilize and reduce tissue iron in diseases of iron overload, said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros.

2021 Market Report on Hepcidin Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 3, 2021

The "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this report the pipeline Target constitutes close to 5 molecules.
  • Hepcidin is a protein encoded by the HAMP gene.
  • It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Retrieved on: 
Wednesday, June 2, 2021

20045078) today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH).

Key Points: 
  • 20045078) today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH).
  • The Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need.
  • Together with our partner Zealand Pharma, we look forward to working closely with the FDA as we explore the potential of the GLP-1/glucagon agonist to improve outcomes for adults with NASH.
  • Boehringer Ingelheim and Zealand Pharma are committed to delivering innovative solutions that address public health challenges of cardiometabolic diseases, including NASH, said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma.

Worldwide Rapid Acting Insulin Industry to 2027 - Sedentary and Unhealthy Lifestyles are Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, May 31, 2021

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027.

Key Points: 
  • The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027.
  • In addition, rapid acting insulin act very quickly, they can lead to an increased chance of hypoglycemia.
  • Some of the rapid acting insulin available in the market include Fiasp, Humalog, NovoRapid, Apidra and others.
  • However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry.

Global Insulin Pumps Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 26, 2021

The "Insulin Pumps Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Insulin Pumps Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global insulin pumps market exhibited moderate growth during 2015-2020.
  • Looking forward, the publisher expects the global insulin pumps market to reach a value of US$ 5.6 Billion by 2026.
  • Insulin pumps are small computerized medical devices that can be clipped on to a belt, pocket or hidden under the clothes.